Cargando…

Loss of Heterozygosity for Kras(G12D) Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism

Loss of heterozygosity (LOH) for KRAS, in which a wild-type KRAS allele is progressively lost, promotes invasive and migratory abilities of pancreatic ductal adenocarcinoma (PDAC) cells and tissues. Moreover, the occurrence of Kras(G12D)-LOH activates nonclassical glutamine metabolism, which is rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yu, Ling, Sunkai, Li, Yuan, Hu, Mingyue, Kong, Bo, Huang, Peilin, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224498/ https://www.ncbi.nlm.nih.gov/pubmed/35743139 http://dx.doi.org/10.3390/ijms23126697

Ejemplares similares

Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2
por: Ma, Yu, et al.
Publicado: (2019)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Distinct serum metabolomics profiles associated with malignant progression in the Kras(G12D) mouse model of pancreatic ductal adenocarcinoma
por: LaConti, Joseph J, et al.
Publicado: (2015)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
por: Diersch, Sandra, et al.
Publicado: (2015)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
por: Farrell, Amy S., et al.
Publicado: (2017)

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?
por: Shen, Henry, et al.
Publicado: (2022)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
por: Kong, Yao, et al.
Publicado: (2023)

HIF‐2α regulates non‐canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma
por: Li, Wenzhu, et al.
Publicado: (2017)

SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression
por: Gao, Chuntao, et al.
Publicado: (2015)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
por: Wang, Yuqiong, et al.
Publicado: (2021)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model
por: Chang, Hui-Hua, et al.
Publicado: (2018)

KRAS(G12D) and TP53(R167H) Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs
por: Principe, Daniel R., et al.
Publicado: (2018)

MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma
por: Ding, Feng, et al.
Publicado: (2017)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Up‐regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma
por: Gao, Junyi, et al.
Publicado: (2020)

Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma
por: Li, Na, et al.
Publicado: (2016)

Porcine pancreatic ductal epithelial cells transformed with KRAS(G12D) and SV40T are tumorigenic
por: Bailey, Katie L., et al.
Publicado: (2021)

Progress in Animal Models of Pancreatic Ductal Adenocarcinoma
por: Kong, Kaiwen, et al.
Publicado: (2020)

Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies
por: Ardalan, Bach, et al.
Publicado: (2021)

Dietary fiber intake and risks of proximal and distal colon cancers: A meta-analysis
por: Ma, Yu, et al.
Publicado: (2018)

Ral GTPase–activating protein regulates the malignancy of pancreatic ductal adenocarcinoma
por: Yoshimachi, Shingo, et al.
Publicado: (2021)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
por: Topham, James T., et al.
Publicado: (2022)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gvboabofekgj2a5mimik09qukg